Login / Signup

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.

Kyriakos P PapadopoulosNehal LakhaniGerald S FalchookGosia RileyJohan BaeckKaren S BrownGilad GordonLidya LeJudy S Wang
Published in: Cancer immunology, immunotherapy : CII (2020)
NCT03790488, December 31 2018.
Keyphrases
  • endothelial cells
  • study protocol
  • clinical trial
  • phase iii
  • induced pluripotent stem cells
  • pluripotent stem cells
  • phase ii
  • binding protein